DF Dent & Co. Inc. continued to hold its stake in Abbott Laboratories (NYSE:ABT) during the first quarter, Holdings Channel reports. The firm owned 11,288 shares of the healthcare product maker’s stock at the end of the first quarter. DF Dent & Co. Inc.’s holdings in Abbott Laboratories were worth $501,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Boston Partners increased its stake in Abbott Laboratories by 5,663.7% in the first quarter. Boston Partners now owns 8,212,035 shares of the healthcare product maker’s stock worth $364,696,000 after buying an additional 8,069,557 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Abbott Laboratories by 11.0% in the first quarter. Bank of New York Mellon Corp now owns 33,796,869 shares of the healthcare product maker’s stock worth $1,500,920,000 after buying an additional 3,344,508 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Abbott Laboratories by 33.8% in the first quarter. Ameriprise Financial Inc. now owns 8,823,399 shares of the healthcare product maker’s stock worth $391,841,000 after buying an additional 2,231,316 shares in the last quarter. Swiss National Bank increased its stake in Abbott Laboratories by 45.3% in the first quarter. Swiss National Bank now owns 6,528,788 shares of the healthcare product maker’s stock worth $289,943,000 after buying an additional 2,035,170 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its stake in Abbott Laboratories by 1,134.8% in the first quarter. Canada Pension Plan Investment Board now owns 2,095,044 shares of the healthcare product maker’s stock worth $93,041,000 after buying an additional 1,925,376 shares in the last quarter. Institutional investors and hedge funds own 70.98% of the company’s stock.

Abbott Laboratories (NYSE ABT) traded down 0.830% on Thursday, reaching $48.365. The company had a trading volume of 568,381 shares. The stock’s 50 day moving average is $49.13 and its 200-day moving average is $45.58. The stock has a market capitalization of $84.03 billion, a P/E ratio of 67.738 and a beta of 1.07. Abbott Laboratories has a 1-year low of $37.38 and a 1-year high of $51.13.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.60 by $0.02. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The business had revenue of $6.64 billion during the quarter, compared to analysts’ expectations of $6.63 billion. During the same period in the previous year, the firm posted $0.55 earnings per share. The company’s revenue was up 24.5% on a year-over-year basis. On average, equities analysts predict that Abbott Laboratories will post $2.49 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, August 15th. Stockholders of record on Friday, July 14th will be paid a $0.265 dividend. The ex-dividend date of this dividend is Wednesday, July 12th. This represents a $1.06 dividend on an annualized basis and a dividend yield of 2.17%. Abbott Laboratories’s payout ratio is presently 149.30%.

WARNING: This piece was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/10/abbott-laboratories-nyseabt-position-maintained-by-df-dent-co-inc.html.

ABT has been the subject of a number of recent research reports. Zacks Investment Research upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and set a $49.00 price target for the company in a research note on Tuesday, May 16th. TheStreet downgraded Abbott Laboratories from a “b” rating to a “c+” rating in a research note on Thursday, May 18th. Barclays PLC boosted their price target on Abbott Laboratories from $50.00 to $52.00 and gave the company an “overweight” rating in a research note on Thursday, April 20th. Morgan Stanley restated an “equal weight” rating and set a $42.00 price target on shares of Abbott Laboratories in a research note on Wednesday, April 19th. Finally, Cowen and Company restated an “outperform” rating and set a $48.00 price target on shares of Abbott Laboratories in a research note on Saturday, April 22nd. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $51.93.

In other news, insider Stephen R. Fussell sold 196,550 shares of Abbott Laboratories stock in a transaction on Thursday, June 8th. The stock was sold at an average price of $46.00, for a total value of $9,041,300.00. Following the completion of the sale, the insider now directly owns 221,488 shares of the company’s stock, valued at $10,188,448. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jared Watkin sold 552 shares of Abbott Laboratories stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $47.97, for a total value of $26,479.44. Following the completion of the sale, the insider now directly owns 47,090 shares of the company’s stock, valued at $2,258,907.30. The disclosure for this sale can be found here. Insiders sold 218,702 shares of company stock valued at $10,149,733 over the last ninety days. Insiders own 0.76% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.